Shots:

• Novartis signs an exclusive commercialization agreement with Glenmark to commercialize three respiratory therapies i.e- Seebri- Onbrize and Ultibro for treating COPD in Brazil. Novartis will be responsible for the manufacturing of therapies
• The focus of the collaboration is to bolster Glenmark’s respiratory franchise and to expand its respiratory portfolio in Brazil. The agreement will be effective from July 01- 2019
• Novartis’ Seebri (glycopyrronium bromide) is long-acting muscarinic receptor antagonist (LAMA)- Onbrize (indacaterol) is an ultra-long-acting- rapid onset β(2)-adrenoceptor agonist and Ultibro is a combination of indacaterol and glycopyrronium- indicated to treat COPD in adults

Click here to read full press release/ article | Ref: Glenmark | Image: Corporate Ethos